Reach Us +1-218-451-2974


Primary And Secondary Prevention Interventions For Cognitive Decline And Dementia - An Overview | 57464
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per google scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Primary and secondary prevention interventions for cognitive decline and dementia - An overview

5th International Conference on Alzheimer’s Disease & Dementia

Flodgren Gerd

National Institute of Public Health, Norway

Posters & Accepted Abstracts: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.C1.022

Background: The prevalence of dementia, including Alzheimer’s Disease (AD), is increasing due to the aging of the world’s population. As there is no cure for dementia, there is a great need to identify effective interventions to delay or prevent its onset. Methods: We searched eight databases from inception and up to January 2016. We included high quality systematic reviews of any intervention that included people who were either cognitively healthy or had mild cognitive impairment, We used standard review methods with independent screening, assessment and data extraction. Results: We identified eight eligible reviews. Five reviews involved interventions (blood pressure or cholesterol lowering drugs, Omega 3 FAs, cognitive training, and aerobic training) targeting cognitively healthy people. Three reviews concerned interventions (cholinesterase inhibitors, Omega 3 FAs, and vitamin E) targeting people with mild cognitive impairment. High to moderate certainty of evidence from seven of these reviews suggest that neither the pharmacological interventions, nor any of the nutritional supplements evaluated are effective in delaying or preventing cognitive decline, dementia or AD. The effects of aerobic training on cognition are uncertain, due to low to very low quality of evidence from one review. Moderate evidence from one review suggest that computerised cognitive training may lead to a small short-term improvement in cognitive function. We found no reviews of interventions to promote other healthy lifestyle changes, e.g. conversion to a healthy diet, decreased alcohol intake, smoking cessation, etc., or addressing other risk factors for dementia, e.g. depression, lack of social interaction, and low educational attainment. Conclusion: Evidence from systematic reviews of effective interventions to prevent cognitive decline, AD and dementia are lacking. Only single faceted interventions have been evaluated in systematic reviews. Due to the multifactorial aetiology of dementia, interventions addressing more than one modifiable risk factor may be needed.

Flodgren has a PhD in Sports Medicine from Umeå University, Sweden. He has for the last eight years worked in the Cochrane Effective Practice and Organisation of care group, first at the Univeristy of Newcastle, and the last five years at Oxford University. She is the first author of a number of Cochrane systematic reviews.

Email: [email protected]